GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271)

GlycoMimetics (NASDAQ:GLYC), a biopharmaceutical company focused on discovering and developing novel small-molecule drug candidates to treat rare diseases, announced today that the Japan Patent Office (JPO) has issued Patent No. 6366150, for uproleselan (GMI-1271).

As quoted in the press release:

“The JPO’s issuance of a patent for uproleselan extends major market intellectual property coverage for this E-selectin antagonist drug candidate,” stated Rachel King, GlycoMimetics’ Chief Executive Officer. “As the need for novel AML treatments continues to grow worldwide, the Japanese patent represents an important component of our intellectual property portfolio. It protects the composition of matter of this innovative approach to treating blood cancer.”

As previously announced, the United States Patent and Trademark Office (USPTO) and European Patent Office have issued patents directed to the composition of matter of uproleselan, pharmaceutical formulations of uproleselan, and methods of treating acute myelogenous leukemia. These patents will also expire in late-2032. In addition to the above coverage. GlycoMimetics has ongoing efforts to secure additional patents on uproleselan and its uses to potentially extend exclusivity beyond 2032.

Click here to read the full press release.